

PURE BIOSCIENCE, INC.  
Form DFAN14A  
December 23, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a)**

**of the Securities Exchange Act of 1934**

**(Amendment No. )**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to §240.14a-12

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

**PURE BIOSCIENCE, INC.**

(Name of Registrant as Specified In Its Charter)

**Richmont Corporation**

**John P. Rochon**

**Theodore Coburn**

**C. James Jensen**

**Thomas J. Reynolds**

**Dr. Martin Kassir**

## Jeffrey P. Bash

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

(1) Amount Previously Paid:

Edgar Filing: PURE BIOSCIENCE, INC. - Form DFAN14A

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

**COALITION TO SAVE PURE FILES PROXY DOCUMENTS WITH SEC,  
URGES PURE S BOARD TO SET AN ANNUAL MEETING DATE**

*For Immediate Release*

**December 23, 2011**

The Coalition to Save Pure, a group of stockholders and director nominees that has nominated a slate of six individuals to replace the current board of directors of Pure Bioscience, Inc. (NASDAQ: PURE), today filed its preliminary proxy statement with the Securities and Exchange Commission.

Pure owns the rights to silver dihydrogen citrate (SDC), an antibacterial, antiviral and antifungal technology.

In the filing, the Coalition outlined its reasons for seeking to replace the current board. We believe that SDC holds substantial promise and that Pure has simply had the wrong people at the helm. They have had more than enough opportunity to prove themselves, but have saddled the Company with operating losses and inflicted substantially diminished share value upon stockholders, the Coalition s filing stated.

The Coalition has also called upon Pure s Board of Directors to set a timely date for the Company s next annual meeting:

It s time to give Pure s stockholders the choice between current management and new leadership. January 19 marks one year since Pure s last annual meeting. We urge Pure s board to schedule the next annual meeting without delay, so that stockholders can express their will and choose who they want to lead their company.

*Additional Information*

The Coalition to Save Pure consists of Jeffrey P. Bash, Theodore J. Coburn, C. James Jensen, Dr. Martin Kassir, Thomas J. Reynolds, Ph.D, John P. Rochon and Richmond Corporation, a Delaware corporation based in Plano, Texas, engaged in private investment and business management services. Richmond and each of Messrs. Bash, Coburn, Jensen, Kassir, Reynolds and Rochon (the Participants ) are or may be deemed to be participants under the rules of the Securities and Exchange Commission ( SEC ) in the solicitation of proxies for the election of their slate of nominees to Pure Bioscience s board of directors. In connection with their intended proxy solicitation, the Participants have filed a preliminary proxy statement with the SEC and intend to file a definitive proxy statement with the SEC to solicit stockholders of Pure Bioscience. **The Participants advise stockholders of Pure Bioscience to read their definitive proxy statement when it becomes available, because it will contain important information. That proxy statement, when filed, and any other relevant documents, are or will be available without charge on the SEC s website at [www.sec.gov](http://www.sec.gov). In addition, the Participants in the solicitation will provide copies of the proxy statement and their other soliciting materials without charge upon request. Requests for copies should be directed to**

**the Participants proxy solicitor, MacKenzie Partners, Inc., toll-free at (800) 322-2885 or collect at (212) 929-5500 or via email at [proxy@mackenziepartners.com](mailto:proxy@mackenziepartners.com). Information regarding the Participants, including their direct or indirect interests in the solicitation, by security holdings or otherwise, is contained in their preliminary proxy statement on Schedule 14A filed with the SEC on December 23, 2011, which is available without charge on the SEC's website at [www.sec.gov](http://www.sec.gov).**